John F. Weidenbruch, Esq.
John Weidenbruch recently joined Biogen Idec biopharmaceutical company, located in Weston, Mass. He is vice president and chief commercial counsel, representing the legal aspects of global commercial affairs.
Prior to joining Biogen Idec, he served as the executive vice president and general counsel at Idenix Pharmaceuticals, a publicly traded pharmaceutical company located in Cambridge, Mass., from September 2006 until September 2010. Earlier, Mr. Weidenbruch served as general counsel at Abraxis BioScience Inc., where he was responsible for all legal aspects of the company, including regulatory, corporate and commercialization activities. Prior to joining Abraxis, Mr. Weidenbruch worked at Amgen for more than 10 years, where he held positions of increasing responsibility including senior associate general counsel of global commercial operations, leading a team of attorneys that, along with day-to-day guidance for commercial activities, supported the launch of new products. Mr. Weidenbruch also served as the assistant general counsel and director of state government relations for the Nonprescription Drug Manufacturers Association where he directed the association’s legislative representation before all 50 state legislatures, boards of pharmacy and regulatory bodies.
Mr. Weidenbruch holds a B.A. from Loyola College in Baltimore and a J.D. from Georgetown University Law Center in Washington, D.C.
Mr. Weidenbruch is a member of the American Kidney Fund (AKF) Board of Trustees. He serves on the Finance and Public Policy Committees.